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Background: The incidence of postoperative nausea and vomiting (PONV) is 50% to 80% after neurosurgery. The
common prophylactic treatment for postoperative nausea and vomiting is a triple therapy of droperidol,
promethazine and dexamethasone. Newer, more effectives methods of prophylaxis are being investigated. We
designed this prospective, double-blind, single-center study to compare the efficacy of ondansetron, a neurokinin-1
antagonist, and aprepitant, as a substitute for droperidol, in the prophylactic treatment of postoperative nausea and
vomiting after neurosurgery.
Methods: After obtaining institutional review board approval; 176 patients, 18 to 85 years of age with American
Society of Anesthesiologists (ASA) classifications I to III, who did not receive antiemetics 24 h before surgery and
were expected to undergo general anesthesia for neurosurgery lasting longer than 2 h were included in this study.
After meeting the inclusion and exclusion criteria and providing written informed consent, patients were randomly
assigned in a 1:1 ratio to one of two treatment groups: aprepitant or ondansetron. The objective of this study was
to conduct a randomized, double-blind, double-dummy, parallel-group and single-center trial to compare and
evaluate the efficacies of aprepitant versus ondansetron. Patients received oral aprepitant 40 mg OR oral dummy
pill within 2 h prior to induction. At induction, a combination of intravenous dexamethasone 10 mg, promethazine
25 mg, and ondansetron 4 mg OR dummy injection was administered. Therefore, all patients received one dummy
treatment and three active PONV prophylactic medications: dexamethasone 10 mg, promethazine 25 mg, and
either aprepitant 40 mg OR ondansetron 4 mg infusion. The primary outcome measures were the episodes and
severity of nausea and vomiting; administration of rescue antiemetic; and opioid consumption for 120 h
postoperatively. Standard safety assessments included adverse event reports, physical and laboratory data,
awakening time and duration of recovery from anesthesia.
Discussion: The results of this comparative study could potentially identify an improved treatment regimen that
may decrease the incidence and severity of postoperative nausea and vomiting in patients undergoing
neurosurgery. Also, this will serve to enhance patient recovery and overall satisfaction of neurosurgical patients in
the immediate postoperative period.
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The overall incidence of postoperative nausea and
vomiting (PONV) is around 30% and as great as 70% to
80% in high-risk individuals [1]. For patients undergoing
neurosurgery the PONV incidence is about 50% to 80%.
Indicators for increased risk of PONV with craniotomy
surgery includes: infratentorial lesion, female gender and
children older than 2 years of age [2]. Although PONV
is rarely fatal, it does increase morbidity by threatening
wound dehiscence, hematoma formation, aspiration,
esophageal rupture, dehydration, and increases in intrao-
cular and intracranial pressures due to acute blood pres-
sure elevations [1]. In addition, patients in the early
postoperative period after craniotomy surgery experien-
cing hypertension have an increased mortality if they de-
velop intracranial hemorrhage [3]. Multiple willingness
to pay studies have shown that patients desire most to
avoid pain and nausea or vomiting, and this has over-
ridden even the fear of a catastrophic anesthetic out-
come [4,5]. Research shows patients are willing to pay
$100 out of pocket to prevent nausea and vomiting [6].
Therefore, PONV results in patient discomfort and dis-
satisfaction, the need for a larger nurse-to-patient ratio,
increased post-anesthesia care unit (PACU) times, unin-
tended admissions, extended postoperative stays and
increased overall healthcare costs [1].
PONV risk can be predicted from three characteristics:
the patient, the procedure and the pharmacotherapy/
anesthesia technique. The patient qualities that increase
PONV risk are: female gender (after puberty), younger
age (which tapers after puberty), non-smoking status,
obesity, anxiety, and a history of PONV/motion sickness
[1]. Length of surgery increases the incidence by approxi-
mately 60% from baseline for each 30 minutes of opera-
tive time [1]. Surgical procedures that increase risk
include: plastic surgery/breast augmentation, middle ear,
tonsillectomy, strabismus, laparoscopic, gynecological,
and neurosurgery (particularly infratentorial cranioto-
mies) [1,2]. Anesthesia techniques can augment PONV
outcomes. General anesthesia increases risk of PONV
11-fold compared with regional anesthesia [1]. Likewise,
less PONV is associated with awake craniotomy com-
pared to general anesthesia [7]. Induction and mainten-
ance of anesthesia with propofol and/or avoiding
inhalational anesthetics reduces PONV. Presurgical hy-
dration with 15 to 20 ml/kg of crystalloid can reduce
the incidence of PONV. Neuromuscular reversal with
neostigmine, especially in doses greater than 2.5 mg
can cause PONV. Avoiding opioids and using alterna-
tive modalities for analgesia (that is, non-steroidal anti-
inflammatory drugs (NSAIDs) such as acetaminophen
and ibuprofen) can reduce the risk of PONV. Oxygen
supplementation during the intraoperative period can
cut the risk of PONV by half [1]. A PONV risk factorchart was developed by Apfel et al. in 1999, identifying
four main risks: female gender, non-smoker, history of
PONV, and the use of perioperative opioids [8]. The
presence of zero, one, two, three, or four of these risk
factors equates to 10%, 20%, 40%, 60%, and 80% risk of
PONV, respectively [8]. The general consensus is to
prophylactically treat those patients with moderate to
high risk for PONV [9].
Despite these findings, PONV is still a common
complication of anesthesia and the number one cause
of unanticipated admission after surgery [1,10]. Emesis
pathophysiology is multifactorial, incited by drugs, en-
vironment, radiation and disease states [11,12]. The act
of vomiting is controlled by multiple areas within the
central nervous system (CNS), including the medulla,
vestibular apparatus, and cerebral cortex [12]. The me-
dulla contains the area postrema (AP), the dorsal motor
nucleus of the vagus, and the nucleus tractussolitarius
(NTS), collectively referred to as the ‘emesis center’.
Additionally, the vestibular apparatus feeds auditory
stimuli and positional changes into the vomiting center,
while cortical structures allow emotions, tastes, sights
and smells to play a role [11]. Numerous signals must
arrive at the emesis center in an appropriate sequence
to stimulate emesis [12]. When these stimuli converge,
outputs activate the lower esophageal sphincter (LES)
and stomach, sympathetic ganglia, respiration, swallow-
ing, and baroreceptors. The resulting sensation of nau-
sea is thought to originate in the cerebral cortex.
Vomiting is a complex process that empties the gastro-
intestinal tract by retrograde phasic contractions [12].
At least 17 neurotransmitters have been detected in the
AP and NTS.
Specific receptors including opioid, dopamine, hista-
mine, cannabinoid, serotonin, acetylcholine, and neuro-
kinin 1 (NK-1) are associated with the vomiting reflex
[12]. Therapeutic options have been aimed at blocking
or augmenting many of these receptors. The first class
of antiemetics is dopamine antagonists of which meto-
clopramide and droperidol are examples. Metoclopra-
mide (Reglan), a prokinetic agent that increases muscle
tone of the lower esophagus sphincter and enhance gas-
tric emptying, is likely to cause nervous system side
effects such as jitteriness, insomnia, sedation, or anxiety
with large doses. Droperidol, a very effective antiemetic,
received a US Food and Drug Administration (FDA)
‘black box’ warning due to potential life threatening
arrhythmias and clinically relevant prolongation of the
QTc interval at high doses [1,13]. Antihistamines (that
is, promethazine, cycline, hydroxyzine, and diphenhydra-
mine) block histamine receptors in the vomiting center,
but frequently cause sedation and dry mouth. Anti-
cholinergic scopolamine patches have the ability to pre-
vent emesis for up to 72 h, but frequently cause
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Serotonin antagonists (that is, ondansetron, dolasetron,
and granisetron) are most effective when given towards
the end of surgery, though rare side effects include head-
ache, constipation and increased liver enzymes [1,14].
The anti-inflammatory agent dexamethasone a synthetic
adrenocortical steroid, used prophylactically before the
induction of anesthesia appears to be an effective antie-
metic. Side effects similar to chronic steroid use, adrenal
insufficiency and immunosuppression, have not been
associated with a single dose [1,15].
For those patients at moderate to high risk, combin-
ation therapy has shown to be more efficacious for
PONV prophylaxis. A common triple therapy regimen
includes droperidol, promethazine, and dexamethasone,
which allows smaller doses to be as effective when dosed
together [1]. Triple therapy practice was affected by the
increased warnings and contraindications for droperidol
issued by the FDA. Droperidol is not currently recom-
mended or used in standard combination therapy for
PONV. Furthermore, PONV can occur up to 5 days after
surgery, and most antiemetic therapy would need fre-
quent redosing [14].
A future approach to preventing PONV is blockade
of substance P and NK-1 receptors. Substance P, named
for the powdered product discovered by Gaddum and
Schild, has been studied since the early 1900s [16].
Current research has established substance P as a
prominent neurotransmitter released from both the
CNS and the peripheral nervous system (PNS) afferent
neurons. Substance P interacts with NK receptors,
which are rhodopsin-like structures coupled to G-pro-
teins. This interaction of neurotransmitter and receptor
is involved in many disease processes including: asthma,
chronic bronchitis, inflammatory bowel disease, cystitis,
migraines, seizures, pain, depression, and emesis [16].
Substance P activity occurs at primary sensory neurons
in the PNS, and produces an inflammatory reaction re-
ferred to as neurogenic inflammation.
More recent research is targeting the relationship be-
tween substance P and the CNS. Animal studies demon-
strated that application of substance P to the emesis
center induced vomiting. Substance P is likely involved
in decreasing gastric pressures, slowing antral motility
and relaxing the LES, all involved in the act of regurgita-
tion [12]. Few human trials exist examining NK-1
antagonists in the prevention of PONV, showing a
decreased incidence. Of further interest, the NK-1 antag-
onist aprepitant may have antiemetic effects as far out
from surgery as 48 h, important with post-discharge
nausea and vomiting and opioid induced emesis [14,17].
The FDA-approved aprepitant, an oral NK-1 antagonist,
for treatment and prevention of cisplatin-induced nausea
and vomiting.Methods
We conducted a randomized, double-blind, double-
dummy, parallel-group, single-center study of high risk
for PONV patients to investigate the administration of
triple antiemetic prophylactic therapy. The objective of
this study was to compare and evaluate the efficacies of
aprepitant versus ondansetron for prophylactic combin-
ation therapy in preventing nausea and vomiting in
neurosurgery patients. The safety of the two triple ther-
apies in these patients was also assessed.
The standard PONV prophylaxis regimen for high-risk
patients at Ohio State University Medical Center
(OSUMC) consists of dexamethasone, promethazine,
and ondansetron. In this study, we used a double-
dummy design to substitute aprepitant for ondansetron
in a 1:1 ratio to determine the relative efficacies of these
two drugs in combination therapy. The study groups
were compared for the number of patients that develop
PONV, the number and total dose of rescue from PONV
medications given postoperatively, and patient satisfac-
tion with their treatment. We hypothesized a signifi-
cantly greater percentage of neurosurgery patients will
experience no vomiting during the immediate 48-h post-
operative period in the prophylactic aprepitant triple
therapy group.
Adult patients, 18 to 85 years of age, scheduled for
neurosurgery requiring opening of the cranium and dura
at OSUMC and who consent in writing to participate in
this study were eligible. Patients who were (1) prisoners,
(2) pregnant women, (3) mentally ill, (4) under the age
of 18 or over the age of 85, (5) graded as American Soci-
ety of Anesthesiologists (ASA) classification V (6) alco-
hol or drug abusers or (7) had a cerebral perfusion
pressure (CPP) greater than 150 mmHg or less than
50 mmHg were excluded from this study.
After receiving approval from The Ohio State Univer-
sity institutional review board, 176 consecutive patients
who meet the inclusion and exclusion criteria and who
give written informed consent to participate in the study
were randomly assigned by the research pharmacist to 1
of 2 experimental groups using a 1:1 ratio. All study
personnel were blinded to group assignment. Patients in
group I received 25 mg promethazine intravenously,
10 mg dexamethasone intravenously, 4 mg ondansetron
intravenously, and an inactive oral dummy pill. Patients
in group II received 25 mg promethazine intravenously,
10 mg dexamethasone intravenously, 40 mg aprepitant
orally, and an inactive dummy intravenous injection.
Thus, all patients received 25 mg promethazine and
10 mg dexamethasone. Because this is a double-blind,
double-dummy study and ondansetron was given intra-
venously whereas aprepitant was given orally, it was ne-
cessary to give patients an oral or intravenous placebo,
depending on their group assignment, for uniformity
Table 2 Demographic and preoperative data
Demographic data Preoperative data
Gender Systolic, diastolic and median
blood pressure
Age Electrocardiography (ECG) recording




Smoking history Hepatic function
Race Cerebral perfusion pressure (CPP)
Motion sickness history
Past reactions to the study drugs
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not contain a placebo arm, though dummy treatment
using placebo was necessary due to the different routes
of medications. Therefore, each patient received the
three drugs in the PONV prophylactic triple cocktail,
plus an intravenous or oral dummy treatment prior to
induction of anesthesia (Table 1). Funding for these
medications was provided internally, through the De-
partment of Anesthesiology.and preoperative data about
each patient in the two groups were recorded (Table 2).
The duration of each surgery (anesthesia time) will be
recorded for each patient. Patients were continuously
monitored in the PACU, surgical intensive care unit
(SICU) and the medical floor for a total of 120 h post-
operatively. Episodes of nausea, vomiting and adminis-
tration of rescue therapy for either nausea or vomiting
were recorded and time stamped by blinded personnel.
In addition, the severity of the nausea or vomiting was
recorded. Nausea will be reported by the patient and
evaluated by the blinded personnel utilizing a standard
verbal response scale (VRS) ranging from 0 to 10, 0
being no nausea and 10 being severe nausea. Vomiting
will be evaluated numerically by the blinded personnel
as either 0, no vomiting, 1, mild vomiting, 2, moderate
vomiting, or 3, severe vomiting. Rescue therapy for
PONV episodes consisted of 4 mg ondansetron. After
the first 24 h of starting the triple therapy antiemetic, an
electrocardiogram (ECG) was recorded as well as blood
drawn for analysis.
Efficacy variables
Efficacy variables were collected based on previously
designed PONV studies [18,19]. The primary efficacy
variable is the percentage of patients with no vomiting
over 0 to 72 h postoperatively across the two treatment
groups.
The secondary efficacy variables are as follows: (1)
proportion of patients with a complete response during
delayed (24 to 120 h; days 2 to 5) and overall (0 to
120 h; days 1 to 5) after neurological surgery and general
anesthesia; (2) proportion of patients with complete con-
trol, defined as no emetic episode, no need for rescueTable 1 Postoperative nausea and vomiting (PONV)
medications and administration
Group I Group II
Preoperative PONV medications:
4 mg ondansetron intravenously
+ placebo PO
40 mg aprepitant PO
+ intravenous placebo
25 mg Promethazine intravenous 25 mg Promethazine intravenous
10 mg dexamethasone intravenous 10 mg dexamethasone intravenous
Postoperative PONV rescue therapy:
Multiple 4 mg ondansetron Multiple 4 mg ondansetronmedication and no more than mild nausea overall (0 to
120 h; days 1 to 5) after neurological surgery and general
anesthesia; (3) assessment of the severity of nausea and
vomiting during acute (0 to 24 h), delayed (24 to 120 h)
and overall (0 to 120 h) intervals after neurological sur-
gery and general anesthesia; (4) assessment of the time
to treatment failure (defined as time to first emetic epi-
sode and/or to first use of rescue medication); (5) assess-
ment of the time to first emetic episode; (6) assessment
the time to significant nausea (defined as nausea rated
≥4 on a 0 to 10 verbal response scale or nausea that
required rescue therapy).
The incidence of any adverse reaction to treatment in
our two experimental groups was recorded. In the
ondansetron-treated patients (group I), all cardiovascu-
lar, gastrointestinal, hepatic, integumentary and neuro-
logic postoperative adverse events was recorded and
analyzed for cause. For instance, treatment-related diar-
rhea, headaches, fever, akathisia and acute dystonic reac-
tions was also recorded and analyzed. Similarly, in the
aprepitant patients (group II) all adverse events related
to the digestive, hemic, lymphatic, nervous, cardiovascu-
lar and respiratory systems was recorded and analyzed
for cause.Statistical methods
From Gan et al. [18] who compared the use of aprepi-
tant 40 mg to ondansetron 4 mg in a similar PONV
study involving patients undergoing open abdominal
surgeries and an overnight hospitalization, 85% of the
patients experienced no vomiting to aprepitant treat-
ment and 67% to ondansetron treatment. For a two-
sided test to compare the two proportions at 0.05 signifi-
cance level, we need n= 88 per group to achieve 80%
power. We sought n = 100 subjects per group to account
for screening and attrition in the study.
The efficacy data was analyzed based on the intention-
to-treat principal. Demographic and other patient char-
acteristics for all randomized patients were reported by
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and so on. Also, we examined the comparability of the
two treatment groups with respect to important pre-
operative factors. Logistic regression was used to test the
primary hypothesis with demographic characteristics as
potential covariates in the model. For the number of
rescue therapy treatments used during the 120-h post-
operative period, Wilcoxon rank sum test was per-
formed. For other secondary endpoints, the analysis
plan was similar to the one for the primary endpoint.
Standard safety assessments included adverse event
reports, physical and laboratory data, awakening time
and duration of recovery from anesthesia.
Discussion
This study could potentially identify an improved
prophylaxis for PONV for patients undergoing neurosur-
gery. This treatment will decrease the incidence and se-
verity of PONV and enhance the overall comfort and
satisfaction of neurosurgical patients in the immediate
postoperative period. We anticipate that this study
would have a moderate to high rate of screen failures
not only due to changes or lack of adherence to the
triple therapy, but due to changes in patients’ condition,
physician preferences, or intolerance to the medications.
Another issue is referred to the lack of adequate assess-
ments for postoperative nausea and vomiting due to
patients lost to follow-up.
Trial status
100 patients were enrolled for this study. Of the 100
patients, were 24 screening failures. Data collection for
the 76 eligible patients was completed and recorded.
Since this a double blind study, statistics and data ana-
lysis on this study need to be completed.
Competing interests
The authors declare that they have no competing interests to report.
Authors’ contributions
SB, the principal investigator, designed the current study, drafted the
manuscript, oversaw revisions, and gave final approval on all aspects of the
study. AV, AU, AA, and SF were involved with the acquisition of data,
drafting and revision of the manuscript, analysis and interpretation of
available results. All authors read and approved the final manuscript
Authors’ information
SB received a MD degree from the National University of Cordoba, Argentina
in 1988. In 1991, he completed an internship in the Department of Surgery
at the Italian Hospital in Cordoba, Argentina. From 1992 to 1997, SB worked
as a Research Associate in the Department of Surgery, Division of
Transplantation at The Ohio State University where he completed a
fellowship in Cellular Immunology and Vascular Biology. He proceeded to do
a residency in general surgery, and later completed his residency in the
Department of Anesthesia at The Ohio State University. In 2008, he obtained
a Certificate of Business Administration. Presently, he is Associate Professor,
Director of Neuroanesthesia and the Neuroanesthesia Fellowship, and
Director of Clinical and Neurological Research in the Department of
Anesthesia at The Ohio State University. SB’s main research interests and
expertise are neuroanesthesia, anesthesia monitoring, and mitigation of risksand discomforts associated with anesthesia. As director of a relatively large
clinical trials research group, SB has mentored numerous research and
neuroanesthesia fellows and currently oversees more than 50 projects in the
areas of anesthesia, neurosurgery, general surgery, and critical care. In 2006,
he was selected as America’s Top Anesthesiologist. He is an active member
of the ASA, SNACC, IARS, SAMBA, and ASRA. SB also serves on the editorial
board of several journals including the Journal of Neurosurgical
Anesthesiology, World Journal of Anesthesiology and International Journal of
Medicine. He has been a faculty at more than 50 national and international
meetings, where he has presented over 200 lectures. SB also has over 40
publications and over 150 abstracts presented at national and international
conferences.
Acknowledgments
We would like to thank the Anesthesia Department at Ohio State University
for their support in carrying out this research protocol and also for providing
the funding to carry out an investigator lead study. Also, thank you to Keri
Hudec our technical editor, for her help on behalf of the department of
Anesthesia.
Author details
1Ohio State University Medical Center, N411 Doan Hall, 410W 10th Ave,
Columbus, OH 43210, USA. 2Ohio State University Medical Center, 2012
Kenny Road, Columbus, OH 43210, USA.
Received: 17 February 2012 Accepted: 16 July 2012
Published: 3 August 2012
References
1. Gan TJ, Meyer T, Apfel CC, Chung F, Davis PJ, Eubanks S, Kovac A, Philip BK,
Sessler DI, Temo J, Tramer MR, Watcha M, Watcha M: Consensus guidelines
for managing postoperative nausea and vomiting. Anesth Analg 2003,
97:62–71.
2. Audibert G, Vial V: Postoperative nausea and vomiting after neurosurgery
(infratentorial and suprtentorial surgery). Ann Fr Anesth Reanim 2004,
23:422–427.
3. Basali A, Mascha EJ, Kalfas I, Schubert A: Relationship between
perioperative hypertension and intracranial hemorrhage after
craniotomy. Anesthesiology 2000, 93:48–54.
4. Macario A, Fleisher LA: Is there value in obtaining a patient’s willingness
to pay for a particular anesthetic intervention? Anesthesiology 2006,
104:906–909.
5. Macario A, Weinger M, Carney S, Kim A: Which clinical anesthesia
outcomes are important to avoid? The perspective of patients. Anesth
Analg 1999, 89:652–658.
6. Gan TJ: Postoperative nausea and vomiting - can it be eliminated? JAMA
2002, 287:1233–1236.
7. Manninen PH, Tan TK: Postoperative nausea and vomiting after
craniotomy for tumor surgery: a comparison between awake craniotomy
and general anesthesia. J Clin Anesth 2002, 14:279–283.
8. Apfel CC, Kranke P, Eberhart LHJ, Roos A, Roewer N: Comparison of
predictive models for postoperative nausea and vomiting. Br J Anaesth
2002, 88:234–240.
9. Murphy MJ, Hooper VD, Sullivan E, Clifford T, Apfel CC: Identification of risk
factors for postoperative nausea and vomiting in the perianesthesia
adult patient. J Perianesth Nurs 2006, 21:377–384.
10. Fortier J, Chung F, Su J: Unanticipated admission after ambulatory
surgery: a prospective study. Canadian J Anaesth 1998, 45:612–619.
11. Watcha MF, White PF: Postoperative nausea and vomiting. Its etiology,
treatment, and prevention. Anesth 1992, 77:162–184.
12. Prommer E, Aprepitant (EMEND): The role of substance P in nausea and
vomiting. J Pain Palliat Care Pharmacother 2005, 19:31–39.
13. Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J:
Prolongation of QTc interval after postoperative nausea and vomiting
treatment by droperidol or ondansetron. Anesthesiology 2005,
102:1094–1100.
14. Kovac AL: Prevention and treatment of postoperative nausea and
vomiting. Drugs 2000, 59:213–243.
15. Henzi I, Walder B, Tramer MR: Dexamethasone for the prevention of
postoperative nausea and vomiting: a quantitative systemic review.
Anesth Analg 2000, 90:186–194.
Bergese et al. Trials 2012, 13:130 Page 6 of 6
http://www.trialsjournal.com/content/13/1/13016. Harrison S, Geppetti P: Substance P. Int J Biochem Cell Biol 2000, 33:555–576.
17. Gan TJ, Kovac A, Lubarsky DA, Phillip BK: PONV Management: Tackling the Practical
Issues. CME/CE 2005–2006. http://www.medscape.com/viewprogram/4990.
18. Apfel CC, Roewer N, Korttila K: How to study postoperative nausea and
vomiting. Acta Anaesthesiol Scand 2002, 46:921–928.
19. Gan TJ, Apfel C, Kovac A, Phillip B, Lawson F: The NK1 receptor antagonist
aprepitant for prevention of postoperative nausea and vomiting.
Anesthesiology 2005, 103:A769.
doi:10.1186/1745-6215-13-130
Cite this article as: Bergese et al.: Aprepitant versus ondansetron in
preoperative triple-therapy treatment of nausea and vomiting in
neurosurgery patients: study protocol for a randomized controlled trial.
Trials 2012 13:130.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
